| Q35764264 | Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. |
| Q45723526 | Assessment of oral transmission using cell-free human immunodeficiency virus-1 in mice reconstituted with human peripheral blood leucocyte |
| Q42450456 | Detection of HIV in oral mucosal cells |
| Q33997299 | Detection of human immunodeficiency virus antibodies in oral fluids |
| Q45435057 | Detection of human immunodeficiency virus type 1 RNA by in situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients |
| Q33684772 | Endogenous salivary inhibitors of human immunodeficiency virus |
| Q56911620 | Expert consensus statement on the science of HIV in the context of criminal law |
| Q37804444 | HIV infection and periodontal diseases: an overview of the post‐HAART era |
| Q40664942 | HIV infection and the dentist. 1. The presence of HIV in saliva and its implications to dental practice |
| Q73825862 | HIV prevalence in dental outpatients in Brazil |
| Q33638612 | HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors. |
| Q38452563 | Human immunodeficiency virus seroprevalence among adults treated for out-of-hospital cardiac arrest in Seattle, Washington, 1989-1993. |
| Q34020111 | Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals |
| Q40731786 | Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva |
| Q33927916 | Innate antiviral defenses in body fluids and tissues |
| Q45743215 | Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva |
| Q34267804 | Oral and systemic health correlates of HIV-1 shedding in saliva |
| Q34526020 | Oral transmission of HIV, reality or fiction? An update |
| Q43935407 | Proviral HIV-1 DNA in gingival crevicular fluid of HIV-1-infected patients in various stages of HIV disease |
| Q40375446 | Risk of acquiring AIDS from salivary exchange through cardiopulmonary resuscitation courses and mouth-to-mouth resuscitation |
| Q77217538 | Risk to the health care worker of HIV infection and how to minimize It |
| Q41697048 | Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. |
| Q28293679 | Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro |
| Q34738486 | The anti-HIV-1 activity associated with saliva |
| Q35185496 | The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay |